ASX:TLXBiotechs
Telix Pharmaceuticals (ASX:TLX) Shares Cool As Profit Momentum Meets Pipeline Delays
Telix Pharmaceuticals stock has cooled off after a strong few months, with a 7% slide over the past week even as the shares are still up double digits over three months. That pullback runs straight into a headline result that shows Telix moving from losses to a clear profit in H1 2026, with net income of US$38.33m on revenue of US$477.35m. The key question for investors is whether this profit turn, supported by the radiopharmaceuticals cash engine, really justifies treating the latest wobble...